The company has described the deal as a ‘strategic investment’ which will help to accelerate the introduction of personalised orthopaedic and craniomaxillofacial implants into the Brazilian market. As part of the deal, Materialise gains access to Engimplan’s local production facility, and has committed to harnessing its 3D printing expertise to enhance Engimplan’s portfolio of products.
As things stand, Engimplan’s offers standard implants and medical instruments. As Materialise comes on board, with its decades’ experience in the medical sector growing medical software portfolio, Engimplan will now begin working towards the delivery of implants designed specifically for each patient.
“This investment by Materialise sends a strong signal to our customers and the industry that we remain committed to developing our innovative solutions that improve the lives of many people, and that we have the confidence and support of a pioneer and global leader in 3D printing,” said Jose Tadeu, CEO of Engimplan. “Together, we can introduce new levels of innovation in the development of personalised implants in Brazil.”
“Surgical planning and 3D printing are increasingly adopted by orthopaedic and CMF surgeons as they understand the positive impact of personalised implants and patient-specific solutions on surgical outcomes,” commented Brigitte de Vet, Vice President and General Manager of Materialise Medical. “With this investment, we will expand our medical product and service portfolio, confirming our commitment to strengthen our position and grow our global presence in the medical industry.”